Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
11/30/2020 12/01/2020 12/02/2020 12/03/2020 12/04/2020 Date
299.05(c) 299.6(c) 302.65(c) 299.7(c) 299.95 Last
3 036 740 1 825 494 1 580 896 2 283 830 169 859 Volume
-1.14% +0.18% +1.02% -0.97% +0.08% Change
More quotes
Financials
Sales 2020 59 925 M 67 284 M 67 284 M
Net income 2020 14 348 M 16 110 M 16 110 M
Net cash position 2020 3 429 M 3 850 M 3 850 M
P/E ratio 2020 18,2x
Yield 2020 3,10%
Sales 2021 62 876 M 70 598 M 70 598 M
Net income 2021 15 592 M 17 507 M 17 507 M
Net cash position 2021 11 577 M 12 999 M 12 999 M
P/E ratio 2021 16,5x
Yield 2021 3,20%
Capitalization 256 B 288 B 288 B
EV / Sales 2020 4,22x
EV / Sales 2021 3,89x
Nbr of Employees 97 735
Free-Float 83,6%
More Financials
Company
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The... 
Sector
Pharmaceuticals
Calendar
12/03Presentation
More about the company
Notations Surperformance© of Roche Holding AG
Trading Rating : Investor Rating :
More Ratings
All news about ROCHE HOLDING AG
12/02GLOBAL MARKETS LIVE: A flurry of acquisitions
12/02ROCHE : Genentech Announces FDA Approval of Gavreto for People With Advanced or ..
AQ
12/02ROCHE : announces FDA approval of Gavreto (pralsetinib) for people with advanced..
AQ
12/02ROCHE : receives FDA Emergency Use Authorization for new test to measure the lev..
AQ
12/01Blueprint Medicines Says FDA Approves Gavreto to Treat Thyroid Cancer
DJ
12/01GENENTECH : Announces FDA Approval of Gavreto (pralsetinib) for People With Adva..
BU
12/01NOVARTIS : Genentech Get Expanded FDA OK of Xolair for Nasal Polyps
DJ
12/01ROCHE : FDA approves Xolair® (omalizumab) for adults with nasal polyps
AQ
12/01ROCHE : Gets FDA Emergency Use OK for Test to Measure Level of SARS-CoV-2 Antibo..
DJ
12/01GENENTECH : Announces FDA Approval of Xolair (omalizumab) for Adults with Nasal ..
BU
12/01GLOBAL MARKETS LIVE: Bank of America, Pfizer, Tesla…
12/01REMINDER : Invitation to Roche's virtual event on key hematology data presented ..
PU
11/30Chugai Files Patent Infringement Lawsuit concerning Edirol Capsules
AQ
11/29Swiss firms narrowly avoid 'Responsible Business' liability as vote divides n..
RE
11/26Business rights or human rights? Swiss vote shines spotlight on companies
RE
More news
News in other languages on ROCHE HOLDING AG
12/03Aktien Schweiz schließen den vierten Tag in Folge schwächer
12/02Aktien Schweiz schließen wenig verändert - Pharmaaktien fest
12/02ROCHE : approbation de la FDA en cancer de la thyroïde
12/02ROCHE : autorisation d'Elecsys Anti-SARS-CoV-2 S par la FDA
12/02EN DIRECT DES MARCHES : Alstom, Total, Peugeot, Lumibird, Interparfums, Salesfor..
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Stock Trading Strategies
ROCHE HOLDING AG - 08/19
Close to an important medium term support level
BUY
More Stock Trading Analysis
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | ROG | CH0012032048 | MarketScreener
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 373,83 CHF
Last Close Price 299,70 CHF
Spread / Highest target 45,5%
Spread / Average Target 24,7%
Spread / Lowest Target -4,90%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
Paul Bulcke Non-Executive Director
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG-4.55%287 762
JOHNSON & JOHNSON2.15%389 985
PFIZER, INC.8.00%226 783
NOVARTIS AG-10.86%207 948
MERCK & CO., INC.-10.03%207 033
ABBVIE INC.18.58%185 357